Enlivex Therapeutics Ltd. (ENLV)

Enlivex Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 14, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	229	26	50	72	115	121
Market Cap Growth	776.77%	-48.77%	-30.73%	-36.72%	-5.58%	39.92%
Enterprise Value	212	2	24	20	33	94
Last Close Price	0.97	1.17	2.70	3.94	6.25	8.43
PB Ratio	1.34	1.09	1.67	1.27	1.35	3.42
P/TBV Ratio	13.12	1.09	1.67	1.27	1.35	3.42
Debt / Equity Ratio	0.04	0.02	0.03	0.09	0.07	0.02
Quick Ratio	6.26	6.56	4.55	7.70	18.09	8.17
Current Ratio	6.43	6.84	5.57	7.92	18.32	8.72
Return on Equity (ROE)	-57.64%	-55.95%	-66.88%	-43.78%	-24.01%	-50.56%
Return on Assets (ROA)	-36.02%	-30.10%	-30.09%	-19.81%	-17.79%	-21.12%
Return on Capital (ROIC)	-40.13%	-35.16%	-33.88%	-21.11%	-18.95%	-25.54%
Return on Capital Employed (ROCE)	-81.60%	-65.00%	-81.70%	-42.30%	-21.30%	-27.20%
Earnings Yield	-5.54%	-58.36%	-57.89%	-42.84%	-12.63%	-9.74%
FCF Yield	-5.22%	-50.96%	-47.31%	-44.24%	-16.73%	-9.91%
Buyback Yield / Dilution	-20.50%	-10.44%	-0.98%	-3.00%	-35.62%	-52.25%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q